Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.

MLA

Petrossian, Gregory, et al. “Outcomes of de Novo Belatacept-Based Immunosuppression Regimen and Avoidance of Calcineurin Inhibitors in Recipients of Kidney Allografts at Higher Risk for Underutilization.” Nephrology (Carlton, Vic.), vol. 27, no. 12, Dec. 2022, pp. 1006–07. EBSCOhost, https://doi.org/10.1111/nep.14120.

APA

Petrossian, G., Ortiz, J., Ortiz, A. C., Koizumi, N., & Plews, R. (2022). Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization. Nephrology (Carlton, Vic.), 27(12), 1006–1007. https://doi.org/10.1111/nep.14120

Chicago

Petrossian, Gregory, Jorge Ortiz, Alejandro Chiodo Ortiz, Naoru Koizumi, and Robert Plews. 2022. “Outcomes of de Novo Belatacept-Based Immunosuppression Regimen and Avoidance of Calcineurin Inhibitors in Recipients of Kidney Allografts at Higher Risk for Underutilization.” Nephrology (Carlton, Vic.) 27 (12): 1006–7. doi:10.1111/nep.14120.